Literature DB >> 9357502

Intralesional electrodesiccation of syringomas.

P Karam1, A V Benedetto, P Karma.   

Abstract

BACKGROUND: Syringomas are common, benign adnexal tumors. In the periorbital area, they pose a cosmetic dilemma for both patients and physicians alike. Many different therapeutic modalities potentially can cause scarring, and recurrences are common.
OBJECTIVE: To develop a treatment method that minimizes scarring and subsequent recurrences.
METHOD: Each syringoma is treated with short bursts of high frequency low voltage electrodesiccation delivered with a fine needle electrode that is inserted into the center of the syringoma, as deeply as the reticular dermis.
RESULTS: Twelve patients treated over a 4-year period showed no permanent adverse effects postoperatively and no recurrences.
CONCLUSIONS: Intralesional electrodesiccation is a safe, nonscarring and, reliable method that can be used to eradicate periorbital syringomas.

Entities:  

Mesh:

Year:  1997        PMID: 9357502     DOI: 10.1111/j.1524-4725.1997.tb00749.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  4 in total

1.  Clinicopathological diversity of syringomas: A study on current clinical and histopathologic concepts.

Authors:  Cornelia S L Müller; Wolfgang Tilgen; Claudia Pföhler
Journal:  Dermatoendocrinol       Date:  2009-11

2.  A technique for periorbital syringomas: intralesional radiofrequency ablation.

Authors:  Li-Ping Huang; Leng Zhang; Xing-Lin Wang; Xiao-Cui Liu; Tian-Yu Jiang; Bi-Weng Lin
Journal:  Int J Ophthalmol       Date:  2012-04-18       Impact factor: 1.779

3.  Syringomas Treated by Intralesional Insulated Needles without Epidermal Damage.

Authors:  Soon-Kwon Hong; Hyun-Jae Lee; Si-Hyung Cho; Jong-Keun Seo; Deborah Lee; Ho-Suk Sung
Journal:  Ann Dermatol       Date:  2010-08-05       Impact factor: 1.444

4.  Unilateral Ulcerating Clear-Cell Syringomas Involving Left Groin in a Non-Diabetic Woman - Report of a Rare Presentation.

Authors:  Angoori Gnaneshwar Rao
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.